Literature DB >> 26562558

Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010.

Raziye Boyar Cetinkaya1, Bjarte Aagnes, Espen Thiis-Evensen, Steinar Tretli, Deidi S Bergestuen, Svein Hansen.   

Abstract

BACKGROUND: Epidemiological studies show an increasing trend in the incidence of neuroendocrine neoplasms (NENs). A significant number of NENs occur in less common primary sites, but they are often excluded from the population-based studies. We studied the incidence trends of all NENs in Norway according to different primary sites.
MATERIALS AND METHODS: Our analyses were based on cancer cases diagnosed between 1993 and 2010 and reported to the national population-based Cancer Registry of Norway. A total of 65 morphological codes were identified as neuroendocrine and stratified into 3 different groups of aggressiveness: low, intermediate and high.
RESULTS: We identified 16,075 NENs of which 49.5% were in women. The median age at diagnosis was 65 years. The most common primary sites were the lung (48.1%) and the gastroenteropancreatic system (18.0%). Stage at diagnosis was local in 40.4% of the cases, regional in 17.5% and distant in 42.1%. The stage distribution was stable throughout the study period. The age-standardized (European) incidence rate (per 100,000 person-years) increased from 13.3 in 1993 to 21.3 in 2010 with an estimated annual increase of 5.1% in women and 2.1% in men. The increase was most pronounced for tumors of intermediate aggressiveness from 3.3 in 1993 to 7.3 in 2010. The largest annual increases were estimated for the adrenal gland (8.8%), the pancreas (6.9%) and the lungs (6.1%).
CONCLUSION: The incidence of NENs increased. Most primary tumors were found in the lungs or in the gastroenteropancreatic system. The increase in the incidence differed according to the primary site, gender and tumor aggressiveness.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26562558     DOI: 10.1159/000442207

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  37 in total

Review 1.  Nutrition and neuroendocrine tumors: An update of the literature.

Authors:  Barbara Altieri; Luigi Barrea; Roberta Modica; Giovanna Muscogiuri; Silvia Savastano; Annamaria Colao; Antongiulio Faggiano
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 2.  Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

Authors:  Sven-Petter Haugvik; Daniel Kaemmerer; Sebastien Gaujoux; Knut Jørgen Labori; Caroline Sophie Verbeke; Ivar Prydz Gladhaug
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

3.  Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry.

Authors:  Ioannis Mintziras; Tobias Keck; Jens Werner; Stefan Fichtner-Feigl; Uwe Wittel; Norbert Senninger; Thorsten Vowinkel; Jörg Köninger; Matthias Anthuber; Bernd Geißler; Detlef Klaus Bartsch
Journal:  Surg Today       Date:  2019-06-25       Impact factor: 2.549

4.  Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.

Authors:  Kendall J Keck; Allen Choi; Jessica E Maxwell; Guiying Li; Thomas M O'Dorisio; Patrick Breheny; Andrew M Bellizzi; James R Howe
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

Review 5.  Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.

Authors:  Peter E Goretzki; Martina T Mogl; Aycan Akca; Johann Pratschke
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

6.  Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI-A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making.

Authors:  Uli Fehrenbach; Siyi Xin; Alexander Hartenstein; Timo Alexander Auer; Franziska Dräger; Konrad Froböse; Henning Jann; Martina Mogl; Holger Amthauer; Dominik Geisel; Timm Denecke; Bertram Wiedenmann; Tobias Penzkofer
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 7.  The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types.

Authors:  Andrew E Hendifar; Deepti Dhall; Jonathan R Strosberg
Journal:  Oncologist       Date:  2018-08-13

8.  A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors.

Authors:  Marta Peri; Edoardo Botteri; Eleonora Pisa; Filippo De Marinis; Antonio Ungaro; Francesca Spada; Chiara Maria Grana; Roberto Gasparri; Lorenzo Spaggiari; Nicole Romentz; Giuseppe Badalamenti; Antonio Russo; Nicola Fazio
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

9.  Influence of Gender on Therapy and Outcome of Neuroendocrine Tumors of Gastroenteropancreatic Origin: A Single-Center Analysis.

Authors:  Martina T Mogl; Eva M Dobrindt; Josephine Buschermöhle; Claudia Bures; Johann Pratschke; Holger Amthauer; Christoph Wetz; Henning Jann
Journal:  Visc Med       Date:  2020-01-20

Review 10.  Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma.

Authors:  Kazhan Mollazadegan; Staffan Welin; Joakim Crona
Journal:  Curr Treat Options Oncol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.